Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06297629

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation Clinical Trial

Official title:
A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Clinical Trial Summary

To learn if ASTX727 given alone or in combination with donor lymphocyte infusion (DLI) can help to control certain types of hematological neoplasms (blood-based cancers) after a stem cell transplant.

Clinical Trial Description

Primary Objectives - To determine the safety and toxicity of ASTX727 with or without donor lymphocyte infusion (type, frequency, severity of adverse events [AEs] and relationship of AEs to ASTX727) in the study population (cohort #1 and cohort #2). - To estimate the complete response (CR) rate of ASTX727 with or without donor lymphocyte infusion (DLI) for the eradication of minimal residual disease (MRD) in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), after hematopoietic stem cell transplantation (cohort #1). - Estimate relapse-free survival (RFS) with the use of ASTX727 as maintenance therapy in participants with high-risk AML and MDS after study entry following hematopoietic stem cell transplantation (cohort #2). Secondary Objectives - Participants with creatinine clearance 40-60 cc/min at enrollment will be observed and reported for safety and toxicity separately. - To determine the overall response and response duration in cohort #1, in participants with MRD detected in the post-transplant setting. - Duration of remission after study entry following allogeneic stem cell transplant for cohort #2. - To determine incidence of acute and chronic graft versus host disease (GvHD) - To evaluate overall survival (OS). Exploratory Objective - To investigate possible relationships between protein and gene expression signatures/mutation profile and DNA methylation in predicting relapse-free survival time to the ASTX727. - To gain insight into clinically relevant genomic factors influencing transplant outcomes, especially into the mechanism of relapse after transplant. - To characterize the composition of different T-cell subsets, and to determine how those correlate with each other and with transplant outcomes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06297629
Study type Interventional
Source M.D. Anderson Cancer Center
Contact Betul Oran, MD
Phone (713) 745-2820
Email boran@mdanderson.org
Status Not yet recruiting
Phase Phase 2
Start date July 31, 2024
Completion date August 31, 2026
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Terminated NCT01185223 - Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation Phase 3
Not yet recruiting NCT01212796 - Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH N/A
Terminated NCT00737113 - Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant Phase 1
Recruiting NCT06028828 - Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Not yet recruiting NCT03964922 - Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation N/A
Completed NCT03467074 - Role of Interferon-λ and Vaccine Response
Completed NCT02273024 - Exercise Prior to Allogeneic Hematologic Stem Cell Transplantation N/A
Recruiting NCT06093334 - Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD N/A
Recruiting NCT03286530 - Ruxolitinib + Allogeneic Stem Cell Transplantation in AML Phase 2
Completed NCT01092026 - Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells N/A
Recruiting NCT01160952 - Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation Phase 2
Recruiting NCT00883714 - Exercise During the Allogeneic Stem Cell Transplantation Phase 3
Completed NCT04628338 - IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation Early Phase 1
Completed NCT06256341 - HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem.
Completed NCT05088941 - Impact of COVID-19 Pandemic on Allogeneic Stem Cell Transplantation Organization : a French Experience
Not yet recruiting NCT06453460 - Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla Phase 2
Recruiting NCT02533947 - Cognition in Allogeneic Stem Cell Transplanted Patients and Sports N/A
Completed NCT01560689 - Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation Phase 2
Completed NCT01929980 - Bortezomib to Treat Significant Complication of HSCT Phase 2